Overview

Improving Quality of Bier Block

Status:
Recruiting
Trial end date:
2020-08-31
Target enrollment:
0
Participant gender:
All
Summary
Intravenous regional anesthesia is one of the well-known techniques of regional anesthesia for short surgical operations on the upper and lower limbs. It was first introduced back in 1908. Later on it was popularized even more for the same purpose by using two tourniquets to isolate an exsanguinated extremity then injection of local anesthesia. It was proved over time to be safe and effective with minimal side effects and complications. Magnesium sulfate (MgSO4) has been used over the 20th century for prevention and treatment of pre-eclamptic and eclampsia seizures during pregnancy because of its superior safety profile over other drugs used for the same purpose. The specific mechanisms of action of magnesium sulfate still unclear but are probably multi-factorial. It may act as a vasodilator on peripheral as well as cerebral vasculature, to decrease peripheral vascular resistance and/or relieve vasoconstriction. Additionally, it may also protect the blood-brain barrier and limit cerebral edema formation, or it may also act as a central anticonvulsant. Fentanyl; was first introduced back in 1990 for palliative use as fentanyl patch. Few years later, it became available in different forms of administration being highly lipophilic. Few years later it became the most widely used synthetic opioid in medicine. It is an opioid analgesic with a rapid onset and short duration of action. It is a potent μ-opioid receptor pure agonist. Fentanyl is 50 to 100 times more potent than morphine. Fentanyl has a relatively wide therapeutic index, which makes it a very safe surgical anesthetic drug when monitored carefully.
Phase:
Phase 2/Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Assiut University
Treatments:
Fentanyl
Lidocaine
Magnesium Sulfate
Criteria
Inclusion Criteria:

- scheduled for short surgical procedures (30 - 60 minutes) distal to elbow

- age 18-55 years old

- ASA I - II

- both genders

- average weight BMI (25 - 35).

Exclusion Criteria:

- seizure diseases

- allergy to the used medicine

- local infection

- patients with sickle cell anemia, Raynaud's disease, scleroderma, myasthenia gravis,
significant cardiac or hepatic diseases.